Worldwide Initiative for Diabetes Education Recommends High-Frequency SCS by Nevro for Diabetic Pain
Written by Arushi Sharma
Good news for people struggling with painful diabetic neuropathy (PDN): Nevro's high-frequency spinal cord stimulation (SCS) therapy has received a thumbs-up from a leading diabetes organization.
Nevro, a global medical device company, receives an endorsement from the Worldwide Initiative for Diabetes Education for its high-frequency (10 kHz) spinal cord stimulation (SCS) in treating painful diabetic neuropathy (PDN).
The consensus statement recommends this therapy when other treatments prove ineffective, based on outcomes from the WorldWIDE Diabetes Virtual Global Summit and detailed in Diabetes Research and Clinical Practice.
The recommendation underscores the effectiveness of Nevro's high-frequency SCS in managing PDN symptoms not adequately controlled by first- or second-line treatments. PDN, impacting over half of those with type 2 diabetes, causes numbness, tingling, and pain affecting quality of life.
Dr. David Caraway, Nevro's Chief Medical Officer, highlights the guidelines' significance, crediting the SENZA-PDN randomized controlled trial for demonstrating the therapy's value.
Aligning with prior recommendations, Nevro's 10 kHz Therapy is the only FDA-approved high-frequency, paresthesia-free SCS system for PDN treatment.
Despite positive clinical outcomes, Nevro's stock has seen a 23.05% decline over the last month. Analysts have revised earnings downward, and the company is not expected to be profitable this year.
However, Nevro's strong balance sheet, with cash reserves exceeding debt, indicates financial stability supporting ongoing initiatives. Investors are advised to consider both clinical advancements and financial metrics for a comprehensive understanding.